1. Home
  2. WEN vs LTGO Comparison

WEN vs LTGO Comparison

Compare WEN & LTGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Wendy's Company (The)

WEN

Wendy's Company (The)

HOLD

Current Price

$9.01

Market Cap

1.5B

ML Signal

HOLD

LTGO

Latigo Biotherapeutics Inc. Common Stock

N/A

Current Price

$22.37

Market Cap

1.2B

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
WEN
LTGO
Founded
1969
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Restaurants
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.2B
IPO Year
2000
2026

Fundamental Metrics

Financial Performance
Metric
WEN
LTGO
Price
$9.01
$22.37
Analyst Decision
Hold
Analyst Count
22
0
Target Price
$8.84
N/A
AVG Volume (30 Days)
9.7M
385.4K
Earning Date
05-08-2026
N/A
Dividend Yield
8.28%
N/A
EPS Growth
N/A
N/A
EPS
0.29
N/A
Revenue
$2,176,891,000.00
N/A
Revenue This Year
$2.26
N/A
Revenue Next Year
$0.94
N/A
P/E Ratio
$30.36
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.07
$17.22
52 Week High
$10.62
$21.71

Technical Indicators

Market Signals
Indicator
WEN
LTGO
Relative Strength Index (RSI) 64.30 85.35
Support Level $7.84 $18.46
Resistance Level $9.45 N/A
Average True Range (ATR) 0.41 1.31
MACD 0.12 0.35
Stochastic Oscillator 98.98 96.70

Price Performance

Historical Comparison
WEN
LTGO

About WEN Wendy's Company (The)

The Wendy's Co is engaged in operating, developing, and franchising a system of distinctive quick-service restaurants serving high-quality food. The company operates through Wendy's U.S., Wendy's International, and Global Real Estate & Development. Wendy's U.S. and Wendy's International include the operation and franchising of restaurants and derive revenues from sales at company-operated restaurants, as well as royalties, franchise fees, and advertising fund collections from franchised restaurants. Global Real Estate & Development includes real estate activities for owned and leased sites that are leased or subleased to franchisees and includes the company's share of income from its Canadian restaurant real estate joint venture.

About LTGO Latigo Biotherapeutics Inc. Common Stock

Latigo Biotherapeutics Inc is a clinical-stage biotechnology company focused on developing non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its flagship product candidates, LTG-001 and LTG-321, are oral Nav1.8 inhibitors being developed for the treatment of acute pain. The company is also developing additional Nav1.8 inhibitor candidates using alternative formulations and delivery approaches.

Share on Social Networks: